Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation
Combines Amgen's Proprietary Antibodies and Xencor's XmAb® Bispecific Antibody Platform to Develop New Therapeutic Candidates Includes Xencor's Preclinical CD38 Bispecific T Cell Engager for Multiple Myeloma Xencor to Receive $45 Million Upfront Payment and Up to $1.7 Billion in Clinical,
View HTML
Toggle Summary Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases
Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases Thousand Oaks, Calif. and Monrovia, Calif. – (Jan. 6, 2011) – Amgen (NASDAQ: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb®5871, an Fc- engineered
View HTML
Toggle Summary Bassil Dahiyat Named One of the World’s Top Young Innovators
Bassil Dahiyat Named One of the World’s Top Young Innovators by Technology Review, MIT’s Magazine of Innovation. Dahiyat To Be Honored September 24-25 at The Emerging Technologies Conference at MIT
View HTML
Toggle Summary Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
Antibodies engineered with Xencor's proprietary Xtend&#8482 technology for increasing antibody half-life
View HTML
Toggle Summary Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement
Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement Monrovia, CA – February 13, 2007. Xencor, Inc., a protein and antibody therapeutics development company, today announced a collaboration with Boehringer Ingelheim to optimize therapeutic monoclonal
View HTML
Toggle Summary Chemical Genomics – CALBIOsummit 2002 April 21,22,23
(BW Healthwire)–April 18, 2002—Xencor’s President and CEO, Dr. Bassil Dahiyat Chairs Panel at CALBIOsummit 2002
View HTML
Toggle Summary Chromos and Xencor announce agreement for use of the ACE System to produce biologics.
Chromos and Xencor announce agreement for use of the ACE System to produce biologics. Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research
View HTML
Toggle Summary Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience
Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience Monrovia, Calif. – January 19, 2010 – A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies
View HTML
Toggle Summary Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells
Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells Monrovia, CA – March 7, 2006 – Engineering the “Fc“ region of monoclonal antibodies (mAbs) increases their toxicity to cancer cells, potentially improving the utility of targeted cancer
View HTML
Toggle Summary Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier
Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier (BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company
View HTML
Xencor © Copyright 2018